Marnac, Inc.

China was probably not a major consideration in Roche's $8bn-plus bet on US biotech InterMune and its mainstay product pirfenidone, but the figure paid for the acquisition may be seen as validation fo

Shionogi has lodged a legal action in the US against InterMune, claiming that the US firm has failed to pay due royalties on sales of the idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone)

Financings The third quarter of 2011 saw biopharmaceutical financings slump in both the number of transactions and the amount of money raised. The 61 financings that closed brought in $1.3 billion, we

By a decisive 9-3 vote, the US FDA's advisory committee on pulmonary drugs on March 9th recommended that the agency approve the new drug application (NDA) from InterMune to market as a treatment its d